Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient

J Antimicrob Chemother. 2022 Aug 25;77(9):2571-2573. doi: 10.1093/jac/dkac206.

Authors

Joseph Pechacek¹, Idris Yakubu², Nicole C Vissichelli¹, David Bruno³, Megan K Morales¹

Affiliations

¹ Department of Internal Medicine, Division of Infectious Diseases, Virginia Commonwealth University, 1000 E. Marshall St., Richmond, VA 23298USA.
² Department of Pharmacy, Virginia Commonwealth University Health, 1250 E. Marshall St., Richmond, VA 23298, USA.
³ Department of Surgery, Hume-Lee Transplant Center, Virginia Commonwealth University, 1250 E. Marshall St., Richmond, VA 23298, USA.

PMID: 35770840
DOI: 10.1093/jac/dkac206

No abstract available

MeSH terms

Antifungal Agents / therapeutic use
Candidiasis
Candidiasis, Invasive* / drug therapy
Echinocandins / therapeutic use
Humans
Liver Transplantation* / adverse effects

Substances

Antifungal Agents
Echinocandins
Rezafungin

Supplementary concepts

Systemic candidiasis